What did @brandiechamberss actually say?
The transcript as captured is essentially unintelligible, a string of disconnected words that don't form coherent medical claims. What we do have is the caption, which tells a more specific story: she says semaglutide helped her "bounce back after 2 babies," going from 198 lbs to 135 lbs. She's also promoting Zappy Health, a telehealth provider, with a discount code. The hashtags include #pcos and #pcosweightloss, which adds clinical context the caption alone doesn't fully explain.
Because the audio transcript is garbled, this fact-check will focus on the written claims in the caption and the implied medical narrative, which is that semaglutide is an effective postpartum and PCOS weight loss tool. That's a specific enough claim to evaluate against the evidence.
Does the science back this up?
For weight loss in adults with obesity, yes, semaglutide has real clinical support. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) found that adults taking 2.4 mg semaglutide weekly lost an average of 14.9% of body weight over 68 weeks, compared to 2.4% for placebo. A 63 lb loss from a 198 lb starting point represents roughly 32% body weight reduction, which is above average for the trials.
On PCOS specifically, the evidence is promising but more limited. A 2023 meta-analysis (Tay et al., 2023, Journal of Clinical Endocrinology and Metabolism) found GLP-1 receptor agonists improved body weight, insulin resistance, and androgen levels in women with PCOS. So the hashtag use isn't without basis. Postpartum use is less studied, and timing matters, especially for breastfeeding women, since semaglutide is not recommended during lactation per current FDA labeling.
What did they get wrong (or right)?
Credit where it's due: the weight loss number is plausible. Losing 63 lbs on semaglutide is within the range of what the drug can do, particularly for someone with a metabolic condition like PCOS. Mentioning a telehealth provider rather than a street vendor or gray-market website is also a better-than-average disclosure for this category of content.
What's missing is context that actually matters to viewers. There's no mention of side effects, no timeline given, and no acknowledgment that results like hers are on the higher end of what most patients experience. The STEP 1 trial's average was about 15% body weight loss. Her claimed loss is more than double that percentage. That doesn't mean it's impossible, but presenting it without context sets unrealistic expectations for the roughly 196,000 people who watched this.
The promotional discount code without clear disclosure of the financial relationship is also a concern from a transparency standpoint, not a clinical one.
What should you actually know?
Semaglutide is a legitimate, FDA-approved medication for chronic weight management under the brand name Wegovy (2.4 mg weekly). It works by mimicking the GLP-1 hormone, slowing gastric emptying and reducing appetite. It is not a quick fix and it is not without side effects: nausea, vomiting, and gastrointestinal distress affect a significant portion of users, with about 44% of STEP 1 participants reporting nausea (Wilding et al., 2021).
For women with PCOS, the drug shows real promise, but it is not a cure for the underlying hormonal condition. Weight loss through any mechanism can improve PCOS symptoms, and GLP-1 agonists appear to have additional metabolic benefits beyond just calorie reduction. Still, individual results vary significantly based on diet, activity, baseline insulin resistance, and adherence.
Postpartum use requires a conversation with a qualified clinician. If you're breastfeeding, semaglutide is contraindicated. If you're not, timing and nutritional adequacy still matter after pregnancy. A telehealth consultation, as she mentions, is a reasonable first step, but it's not a shortcut past medical evaluation.